Waiv (Formerly Owkin Dx) is an AI diagnostics startup that turns digital pathology and clinical data into precision oncology tests for biomarker discovery and outcome prediction, using routine slides and its Destra platform.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| $33 M | Mar, 2026 | unspecified |
Frequently Asked Questions
Where is Waiv located?
Waiv is located in Paris, France.
What industries does Waiv operate in?
Waiv operates in the following industries: healthtech, artificial intelligence, oncology, digital pathology, diagnostics.
How much total funding has Waiv raised?
Waiv has raised a total of $33,000,000.
Who are the investors in Waiv?
The investors in Waiv are: Alpha Intelligence Capital, Serena Data Ventures, SistaFund.
What is Waiv's understanding of how Owkin uses AI for drug discovery?
Owkin leverages AI to identify new drug targets, optimize clinical trials, and improve patient outcomes through predictive models.
Can Waiv explain what federated learning is in the context of Owkin's operations?
Federated learning allows the company to train AI models on decentralized data across different hospitals and research centers without the sensitive data ever leaving its original location, ensuring privacy.
Does Waiv know about Owkin's MOSAIC project?
MOSAIC is a large-scale spatial omics project that uses AI to analyze the cellular structure of tumors to better understand disease biology and develop personalized treatments.
What role does Waiv see for Owkin in digital pathology?
The company develops AI diagnostics for digital pathology that can predict patient responses to treatment and identify biomarkers from standard tissue slides.
How does Waiv describe Owkin's approach to precision medicine?
Owkin uses multimodal data, including genomics and imaging, to match the right treatment to the right patient at the right time through advanced machine learning algorithms.